UNCY Investors: Robbins LLP Investigates Securities Fraud Class Action Against Unicycive Therapeutics, Inc.

Robbins LLP is investigating allegations that Unicycive Therapeutics, Inc. misled investors about the readiness of its drug prospect, oxylanthanum carbonate, for hyperphosphatemia treatment in chronic kidney disease patients. The company's stock price fell 40% after an FDA inspection revealed cGMP compliance deficiencies at a third-party manufacturing vendor and another 30% after a Complete Response Letter citing the same deficiencies. Shareholders who purchased or acquired UNCY securities between March 29, 2024, and June 27, 2025, may be eligible to participate in the class action.

New York, Sept. 02, 2025 — Robbins LLP has announced the filing of a class action lawsuit against Unicycive Therapeutics, Inc. (NASDAQ: UNCY), alleging that the company misled investors about the readiness of its drug prospect, oxylanthanum carbonate, for treating hyperphosphatemia in chronic kidney disease patients [3].

The lawsuit, filed in the United States District Court for the Northern District of California, seeks damages for investors who purchased or acquired UNCY securities between March 29, 2024, and June 27, 2025 [3]. The complaint alleges that Unicycive violated federal securities laws by making false and misleading statements and failing to disclose material information, specifically regarding the company's ability to satisfy the FDA's manufacturing compliance requirements and the regulatory prospects of its drug candidate [3].

On June 10, 2025, Unicycive announced that the FDA had identified deficiencies in current good manufacturing practice (cGMP) compliance at a third-party manufacturing vendor, leading to a significant drop in the company's stock price. The stock fell $3.68 per share, or 40.89%, to close at $5.32 per share [1]. Subsequently, on June 30, 2025, Unicycive disclosed that the FDA had issued a Complete Response Letter for the drug candidate, citing the same cGMP deficiencies. This announcement resulted in a further decline in the stock price, falling $2.03 per share, or 29.85%, to close at $4.77 per share [1].

Investors who purchased or acquired UNCY securities during the class period are encouraged to contact Robbins LLP to discuss their legal rights. The deadline to ask the court to appoint a lead plaintiff is October 14, 2025 [3].

References:
[1] https://www.globenewswire.com/news-release/2025/09/03/3143943/683/en/DEADLINE-ALERT-Faruqi-Faruqi-LLP-Investigates-Claims-on-Behalf-of-Investors-of-Unicycive-Therapeutics.html
[2] https://www.morningstar.com/news/globe-newswire/9522137/deadline-alert-faruqi-faruqi-llp-investigates-claims-on-behalf-of-investors-of-unicycive-therapeutics
[3] https://www.globenewswire.com/news-release/2025/09/02/3142930/1087/en/Pomerantz-Law-Firm-Announces-the-Filing-of-a-Class-Action-Against-Unicycive-Therapeutics-Inc-and-Certain-Officers-UNCY.html